JP2024523838A5 - - Google Patents
Info
- Publication number
- JP2024523838A5 JP2024523838A5 JP2023575788A JP2023575788A JP2024523838A5 JP 2024523838 A5 JP2024523838 A5 JP 2024523838A5 JP 2023575788 A JP2023575788 A JP 2023575788A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2024523838 A5 JP2024523838 A5 JP 2024523838A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/099228 | 2021-06-09 | ||
| CN2021099228 | 2021-06-09 | ||
| PCT/CN2022/097889 WO2022258015A1 (en) | 2021-06-09 | 2022-06-09 | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024523838A JP2024523838A (ja) | 2024-07-02 |
| JP2024523838A5 true JP2024523838A5 (https=) | 2025-06-18 |
| JPWO2022258015A5 JPWO2022258015A5 (https=) | 2025-06-18 |
Family
ID=84425689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575788A Pending JP2024523838A (ja) | 2021-06-09 | 2022-06-09 | Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250282881A1 (https=) |
| EP (1) | EP4352108A4 (https=) |
| JP (1) | JP2024523838A (https=) |
| KR (1) | KR20240019797A (https=) |
| CN (1) | CN117529503A (https=) |
| AU (1) | AU2022288037A1 (https=) |
| CA (1) | CA3221866A1 (https=) |
| IL (1) | IL308918A (https=) |
| TW (1) | TW202315893A (https=) |
| WO (1) | WO2022258015A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110337448B (zh) * | 2016-12-23 | 2023-08-08 | 瑞美德生物医药科技有限公司 | 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| WO2019094574A1 (en) * | 2017-11-09 | 2019-05-16 | Medimmune, Llc | Bispecific fusion polypeptides and methods of use thereof |
| CN118047873A (zh) * | 2017-12-29 | 2024-05-17 | 圆祥生技股份有限公司 | 调节免疫检查点作为癌症治疗的单特异性蛋白质 |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN112739717B (zh) * | 2018-06-29 | 2025-02-11 | 璟尚生物制药公司 | 三特异性拮抗剂 |
| CN119798453A (zh) * | 2018-11-13 | 2025-04-11 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| CN110003338B (zh) * | 2019-04-16 | 2021-04-23 | 北京免疫方舟医药科技有限公司 | 抗ox40抗体及其应用 |
| WO2021104434A1 (en) * | 2019-11-27 | 2021-06-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS |
-
2022
- 2022-06-09 JP JP2023575788A patent/JP2024523838A/ja active Pending
- 2022-06-09 KR KR1020247000219A patent/KR20240019797A/ko active Pending
- 2022-06-09 TW TW111121529A patent/TW202315893A/zh unknown
- 2022-06-09 AU AU2022288037A patent/AU2022288037A1/en active Pending
- 2022-06-09 EP EP22819612.7A patent/EP4352108A4/en active Pending
- 2022-06-09 CA CA3221866A patent/CA3221866A1/en active Pending
- 2022-06-09 IL IL308918A patent/IL308918A/en unknown
- 2022-06-09 WO PCT/CN2022/097889 patent/WO2022258015A1/en not_active Ceased
- 2022-06-09 US US18/568,252 patent/US20250282881A1/en active Pending
- 2022-06-09 CN CN202280040981.5A patent/CN117529503A/zh active Pending